Latest Biotech News

Bristol Myers Squibb and Johnson & Johnson halted one of three Phase III trials of milvexian, a selective factor XIa inhibitor, after an interim analysis showed futility for the acute coronary...

Lundbeck submitted an unsolicited higher cash offer for Avadel Pharmaceuticals, challenging a prior agreement between Avadel and Alkermes and igniting a bidding war over Lumryz, a marketed...

The U.S. FDA revised the label for Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy Elevidys, adding a boxed safety warning and limiting use to ambulatory patients, and requested...

European venture firm Medicxi closed a €500 million Fund V to back asset‑centric biotechnology companies and opportunistic later‑stage investments. The oversubscribed fund continues Medicxi’s...

The University of Texas MD Anderson Cancer Center launched a $2.5 billion philanthropic campaign, 'Only Possible Here — The Campaign to End Cancer,' aimed at accelerating cancer research,...

Researchers reported multi‑omics and physiologic analyses from a pig‑to‑human kidney xenotransplant in a brain‑dead recipient, mapping immune responses over a 61‑day period and identifying...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended five new products, including a gene therapy developed by Fondazione Telethon for Wiskott‑Aldrich...

Merck agreed to acquire Cidara Therapeutics for $9.2 billion to secure CD-388, a late-stage, long-acting antiviral designed to prevent influenza. The deal gives Merck a phase‑3 program that showed...

The U.S. Food and Drug Administration revised the label for Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys, adding a boxed safety warning and restricting use to ambulatory patients...

Lundbeck submitted an unsolicited, higher offer for Avadel Pharmaceuticals, topping Alkermes’ earlier $2.1 billion agreement and setting off a bidding standoff for the Dublin‑based sleep‑disorder...

The FDA approved Kura Oncology and Kyowa Kirin’s ziftomenib (Komzifti) to treat relapsed or refractory acute myeloid leukemia with NPM1 mutations, based on phase II Komet‑001 data showing...

Pfizer completed its acquisition of Metsera in a deal worth up to $10 billion, securing a fast‑acting amylin analog and a long‑acting GLP‑1 asset in a crowded obesity market. The close ends a...

Researchers performed comprehensive multi‑omic and physiological profiling on a genetically engineered pig kidney transplanted into a brain‑dead human recipient and identified antibody‑ and...

The Terasaki Institute and Caltech secured a $2.8 million CIRM Discovery grant to study early human embryo formation using stem‑cell models, signaling renewed institutional investment in...

Researchers released two AI‑driven advances: DeepTarget, a computational platform that predicts anti‑cancer mechanisms of small molecules and challenges single‑target drug paradigms; and...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued recommendations that include a Sanofi drug for type‑1 diabetes, Eli Lilly’s oral selective estrogen...

The Association for Molecular Pathology’s AMP Group released draft guidelines for interpreting and reporting cancer sequencing variants, covering biomarkers for therapy response/resistance, liquid...

Merck agreed to acquire San Diego biotech Cidara Therapeutics for $9.2 billion to secure CD‑388, a long‑acting antiviral aimed at season‑long prevention of influenza A and B. The deal prices...

Pfizer completed its acquisition of Metsera in a transaction worth up to $10 billion, gaining the obesity biotech’s fast‑acting amylin/GLP assets and a long‑acting GLP‑1. The deal ends a...

Danish drugmaker Lundbeck filed an unsolicited offer for Avadel Pharmaceuticals that topped an earlier agreement between Avadel and Alkermes, igniting a cross‑border bidding tussle over a marketed...